| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:457-464.)
© 2004 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Division of Cardiology, Tufts-New England Medical Center, Boston, Mass (J.E.U.); Henry Low Heart Center, Hartford Hospital, Hartford, Conn, and the University of Connecticut School of Medicine, Farmington (G.V.H.); Cardiovascular Division, Yale University School of Medicine, New Haven, Conn (F.J.T.W.); Idaho Cardiology Associates, Boise, Idaho (A.C., D.H.); Northern California Medical Associates, Santa Rosa, Calif (P.S.C.); Division of Nuclear Medicine, University of Maryland School of Medicine, Baltimore, Md (V.D.); Division of Cardiology, University of Southern California Medical School, Los Angeles, Calif (R.H.); Division of Nuclear Medicine, Brigham and Womens Hospital, Boston, Mass (M.D.); King Pharmaceuticals Research and Development, Cary, NC (J.R.J., R.J.B.); and Cardiovascular Division, Mayo Clinic, Rochester, Minn (R.J.G.).
Correspondence to James E. Udelson, MD, Division of Cardiology, Box 70, Tufts-New England Medical Center, 750 Washington St, Boston, MA 02111. E-mail judelson{at}tufts-nemc.org
Received September 18, 2003; de novo received October 29, 2003; revision received December 3, 2003; accepted December 5, 2003.
Background Dipyridamole and adenosine cause frequent side effects as a result of nonspecific adenosine receptor stimulation. Selective agonism of the adenosine A2A receptor should result in a similar degree of coronary vasodilation (and thus similar perfusion images) with fewer side effects.
Methods and Results In a multicenter, randomized, single-blind, 2-arm crossover trial, 240 patients underwent 2 single photon emission computed tomographic (SPECT) imaging studies in random order, first after pharmacological stress with adenosine and a second study with the selective adenosine A2A receptor agonist binodenoson, using 1 of 4 dosing regimens. Safety, tolerability, and SPECT image concordance between the 2 agents were examined. Exact categorical agreement in the extent and severity of reversible perfusion defects ranged from 79% to 87%, with kappa values from 0.69 to 0.85, indicating very good to excellent agreement between binodenoson and adenosine. The risk of any safety event/side effect was significantly lower with any dose of binodenoson than with adenosine (P
0.01) because of a dose-related reduction in subjective side effects, as objective events were infrequent. There was a reduction in the severity of chest pain, dyspnea, and flushing in all binodenoson doses compared with adenosine (P<0.01), and the magnitude of severity reduction was dose-related.
Conclusions The selective adenosine A2A receptor agonist binodenoson results in an extent and severity of reversible perfusion defects on SPECT imaging similar to nonselective adenosine receptor stimulation, accompanied by a dose-related reduction in the incidence and severity of side effects.
Key Words: scintigraphy adenosine imaging nuclear medicine
This article has been cited by other articles:
![]() |
J. J. Murray, J. M. Weiler, L. B. Schwartz, W. W. Busse, R. K. Katial, R. F. Lockey, E.R. McFadden Jr, G. C. Pixton, and R. J. Barrett Safety of Binodenoson, a Selective Adenosine A2A Receptor Agonist Vasodilator Pharmacological Stress Agent, in Healthy Subjects With Mild Intermittent Asthma Circ Cardiovasc Imaging, November 1, 2009; 2(6): 492 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H. Botvinick Current Methods of Pharmacologic Stress Testing and the Potential Advantages of New Agents J. Nucl. Med. Technol., March 1, 2009; 37(1): 14 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Heinonen, S. V. Nesterov, K. Liukko, J. Kemppainen, K. Nagren, M. Luotolahti, P. Virsu, V. Oikonen, P. Nuutila, U. M. Kujala, et al. Myocardial blood flow and adenosine A2A receptor density in endurance athletes and untrained men J. Physiol., November 1, 2008; 586(21): 5193 - 5202. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Udelson Lessons from the development of new adenosine A2A receptor agonists. J. Am. Coll. Cardiol. Img., May 1, 2008; 1(3): 317 - 320. [Full Text] [PDF] |
||||
![]() |
S C Chua, R H Ganatra, D J Green, and A M Groves Nuclear cardiology: myocardial perfusion imaging with SPECT and PET Imaging, September 1, 2006; 18(3): 166 - 177. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Dhalla, M.-Y. Wong, W.-Q. Wang, I. Biaggioni, and L. Belardinelli Tachycardia Caused by A2A Adenosine Receptor Agonists Is Mediated by Direct Sympathoexcitation in Awake Rats J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 695 - 702. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Hendel, T. M. Bateman, M. D. Cerqueira, A. E. Iskandrian, J. A. Leppo, B. Blackburn, and J. J. Mahmarian Initial Clinical Experience With Regadenoson, a Novel Selective A2A Agonist for Pharmacologic Stress Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2069 - 2075. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Miller Impact of Selective Adenosine A2A Receptor Agonists on Cardiac Imaging: Feeling the Lightning, Waiting on the Thunder J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2076 - 2078. [Full Text] [PDF] |
||||
![]() |
P. Voci, F. Pizzuto, and F. Romeo Coronary flow: a new asset for the echo lab? Eur. Heart J., November 1, 2004; 25(21): 1867 - 1879. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |